Neal Shore, MD

Neal Shore, MD, director, Carolina Urologic Research Center, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.

The landscape has evolved dramatically due, in part, to the increased understanding of advanced disease, which led to the approval of 5 encouraging checkpoint inhibitor therapies, and approval of other novel therapies as well. These are truly remarkable improvements, Shore says.

We have also gained improved understanding of the use of immunotherapy in the frontline, as well as in the second-line and maintenance settings for patients with metastatic urothelial carcinoma. Among other advances in the field, Shore highlights the approval of erdafitinib (Balversa) and enfortumab vedotin-ejfv (Padcev), and these therapies all provide expanded treatment options for patients with metastatic disease who either failed or weren’t candidates for radical cystectomy.

Articles

Neal Shore, MD, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.

Expert Highlights Advances in Treatment Landscape for Advanced Bladder Carcinoma

Neal Shore, MD, medical director of Carolina Urologic Research Center, discusses corticosteroid-associated adverse events with low-dose prednisone given with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).

To better understand side effects associated with abiraterone plus prednisone, investigators looked at patients in two large global phase III trials, COU-AA-301 and COU-AA-302. Patients in both studies received either the combination or prednisone alone for treatment of mCRPC, explains Shore.

Investigators determined that the difference between those patients who received abiraterone plus prednisone twice a day versus those who just received prednisone were completely inconsequential when it came to hyperglycemia, weight gain, or weight increase, says Shore.

Neal Shore, MD | Authors

Articles

Expert Highlights Advances in Treatment Landscape for Advanced Bladder Carcinoma

Dr. Neal Shore on Lack of Corticosteroid-Associated Adverse Events with Prednisone Plus Abiraterone